Ex-vivo evaluation of gene therapy vectors in Human pancreatic (cancer) tissue slices

World Journal of Gastroenterology

Volumn 15, Issue 11, 2009, Pages 1359-1366

  van Geer, Michael A ^a   Kuhlmann, Koert F D ^a   Bakker, Conny T ^a   ten Kate, Fibo J W ^a   Oude Elferink, Ronald P J ^a   Bosma, Piter J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adenocarcinoma; Adenovirus; Ex vivo; Pancreas; Tissue slice technology

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RED FLUORESCENT PROTEIN; VIRUS VECTOR; AMYLASE;

ARTICLE; CANCER TISSUE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO GENE TRANSFER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; PANCREAS CANCER; PANCREATICODUODENECTOMY; REPORTER GENE; TISSUE CULTURE; TISSUE SLICE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; ADENOVIRUS; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; LENTIVIRINAE; METHODOLOGY; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PLASMID; SECRETION; XENOGRAFT;

ADENOVIRIDAE; AMYLASES; ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PLASMIDS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 65649125540     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.1359     Document Type: Article

References (28)

1. Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007; 13: 4423-4430
2. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40: 549-558
3. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615
4. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429-432
5. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645
6. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139
7. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98
8. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561
9. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315
10. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther 2001; 8: 969-976
11. Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004; 15: 1034-1044
12. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218
13. Hoem D, Dalen H, Andrén-Sandberg A, Höstmark J. Nonadhesive organ culture of human exocrine pancreatic cells with their stroma. Pancreas 2002; 25: 71-77
14. Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Halldén G. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 2005; 11: 351-360
15. de Kanter R, Monshouwer M, Meijer DK, Groothuis GM. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to nonhepatic tissues. Curr Drug Metab 2002; 3: 39-59
16. Marsman WA, Buskens CJ, Wesseling JG, Offerhaus GJ, Bergman JJ, Tytgat GN, van Lanschot JJ, Bosma PJ. Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo. Cancer Gene Ther 2004; 11: 289-296
17. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004; 10: 8697-8703
18. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, Hayakawa T. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730-735
19. Ma L, Bluyssen HA, De Raeymaeker M, Laurysens V, van der Beek N, Pavliska H, van Zonneveld AJ, Tomme P, van Es HH. Rapid determination of adenoviral vector titers by quantitative real-time PCR. J Virol Methods 2001; 93: 181-188
20. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002; 36: 459-465
21. Seppen J, Bakker C, de Jong B, Kunne C, van den Oever K, Vandenberghe K, de Waart R, Twisk J, Bosma P. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther 2006; 13: 1085-1092
22. Reyes G, Villanueva A, García C, Sancho FJ, Piulats J, Lluís F, Capellá G. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56: 5713-5719
23. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-1535
24. Rots MG, Elferink MG, Gommans WM, Oosterhuis D, Schalk JA, Curiel DT, Olinga P, Haisma HJ, Groothuis GM. An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. J Gene Med 2006; 8: 35-41
25. Sphyris N, Logsdon CD, Harrison DJ. Improved retention of zymogen granules in cultured murine pancreatic acinar cells and induction of acinar-ductal transdifferentiation in vitro. Pancreas 2005; 30: 148-157
26. Grill J, Lamfers ML, van Beusechem VW, Dirven CM, Pherai DS, Kater M, Van der Valk P, Vogels R, Vandertop WP, Pinedo HM, Curiel DT, Gerritsen WR. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 2002; 6: 609-614
27. Lam JT, Bauerschmitz GJ, Kanerva A, Barker SD, Straughn JM, Wang M, Barnes MN, Blackwell JL, Siegal GP, Alvarez RD, Curiel DT, Hemminki A. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377-387
28. Zaia JA. The status of gene vectors for the treatment of diabetes. Cell Biochem Biophys 2007; 48: 183-190